www.fdanews.com/articles/145687-halozyme-falls-after-fda-demands-more-data
Halozyme Falls After FDA Demands More Data
April 17, 2012
Halozyme Therapeutics plunged the most in almost eight years after U.S. regulators requested more information on the company’s blood product used to boost weak immune systems, delaying the treatment’s possible approval.
Bloomberg
Bloomberg